Mouse and Rat Model Generation by CIPHE

Mouse and Rat Model Generation

by CIPHE

Service Description:

Discovering gene function is a key stage in the basic understanding of functional genomics, disease pathogenesis, and new therapy development. CIPHE develops customised cellular and rodent models as advanced tool for modelling of human disease and their genetic validation and characterisation in many therapeutic areas (immunology, neurology, rare-diseases, auto-immunity, inflammation, infection, cancer). CIPHE technologies include ES-cell based and CRISPR-Cas9 genome editing, introducing knock-in and knock–out mutations, point mutation, adding new functionality (human orthologues) and multi-task allels. CIPHE carries out gene editing and the engineering of different cell lines. It develops mouse models using C57BL/6N ES cells, and supplies them in a SOPF status under quality management system (ISO9001). CIPHE offers: constitutive knockout; conditional knock-out (floxed allels); conditional knock-in (i.e for point mutation), tissue-specific expression of iCre; tissue-specific expression of creERT2, overexpression through Harbor locus (like Rosa 26 or Tiger) and humanised gene/locus depending of the demands. These models are used to study: gene function, target validation and compound specificity/toxicity. CIPHE has advanced expertise in knock-in mouse whether to insert reporter to track gene expression or to add a new functionality (human orthologues). These models allow us to follow: gene expression, cell/protein trafficking through fluorescent reporters, genetic cell ablation in vivo by a human DTR cassette, interactomics and signalosomics using twin Strep Tag and multianalytic alleles (multitask alleles using several cassettes).

Included in the Service:

CIPHE offers a comprehensive pipeline from the generation of advanced customised preclinical rodent models to the establishment, maintenance and cryopreservation of genetically modified mouse lines under a quality management system (ISO9001). Our services include: advice and design of an optimised strategy; preparation of all materials for injection (DNA, vectors, sgRNA, Cas9 mRNA, ES cells); injection of genetic material to generate F0 mutant animals; germline transmitted F1 animals; genotyping of F0 animals and delivery of F0 candidates; off-target analysis in F0 founders; germline breeding of F0 founders to achieve germline transmission; off-target analysis in germline transmitted F1 animals. We generate custom mouse models using C57BL/6N ES cells. All models are supplied in specified and opportunistic pathogen free (SOPF) status.

How to apply for the INFRAFRONTIER Mouse Model Generation service?

Please click the button below to fill out our Service Request Form or Pbagnpg hf if you have any questions.

If you have a preferred service provider, please indicate it in the form.

Request Our Service Here

Get to know the provider:

The Centre of ImmunoPHEnomics (CIPHE) is the Center for Technological Resources, Services and Research. (Inserm US012; CNRS UAR 3367; Aix-Marseille University; Phenomin; Celphedia).
CIPHE has a recognised expertise in mouse genetics, genome editing and immunology. CIPHE is a suite of integrated technological units (platforms) specialised in the development and characterisation of pre-clinical in vitro and in vivo models. CIPHE develops mice and rat models mimicking human diseases in many therapeutic domains (immunology, neurology, rare-diseases, auto-immunity, inflammation, infection, cancer).

CIPHE performs phenotypic and functional characterisation of mice and rat models in normal and pathological conditions (inflammation, autoimmunity, cancer, infection).

The CIPHE core facilities make use of their state-of-the-art competences, infrastructure and equipment in the research projects from the molecular to the organism scale by modelling and mimicking human diseases, deciphering the mechanisms of pathologies and the mode of action of therapies. CIPHE pursues Research and Development activities aimed at implementing cutting-edge technologies and improving existing preclinical in vitro and in vivo models.

CIPHE participates in several national and international research programmes and alliances (ERC, ANR, Labex, RHU, PIA and European projects) focusing on mouse genetics, immunology, infection, cancer and rare diseases. CIPHE is also a founding member of the Phenomin National Infrastructure and Celphedia. It is a member of INFRAFRONTIER, IMPC, ISIDORe, GDR Organoids, and Virocrib.

Learn more about CIPHE here.

Relevant Publications

Robert F, Benchenouf F, Ha MN, et al. Placental growth factor modulates endothelial NO production and exacerbates experimental hepatopulmonary syndrome. JHEP Rep. 2024; 7(3):101297 doi: 10.1016/j.jhepr.2024.101297
Demerlé C, Gorvel L, Mello M, et al. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors. J Immunother Cancer. 2023; May;11(5):e006348 doi: 10.1136/jitc-2022-006348
Roncagalli R, Hauri S, Fiore F, et al. Quantitative proteomics analysis of signalosome dynamics in primary T cells identifies the surface receptor CD6 as a Lat adaptor-independent TCR signaling hub. *Nat Immunol. 2014; Apr;15(4):384-392 doi: 10.1038/ni.2843